Sight Sciences Intrinsic Value – SIGHT SCIENCES Releases Financial Report for Fourth Quarter of FY2022 Ending March 13 2023
March 23, 2023
Earnings Overview
SIGHT SCIENCES ($NASDAQ:SGHT) released their financial report for the fourth quarter of FY2022 on December 31 2022, which ended on March 13 2023. The company reported a total revenue of -16.9 million USD, a 6.1% reduction compared to the same period in the prior year. Net income, however, increased by 39.9% year-over-year to 20.5 million USD.
Transcripts Simplified
I’m Tom Smith, the company’s CEO. With me on the call today are Dr. Christina Marshall, CFO and Peter White, Head of Business Development.
However, our sales growth in Europe remained strong and we are on track to meet our goal of doubling our sales in Europe this year. As market conditions improve, we will resume these activities and expect to begin to see improved growth in this area going forward. Looking ahead to the rest of the year, we remain focused on driving growth through new product launches and continued expansion into key international markets. We are also investing in our digital presence, which will allow us to better engage with physicians and patients around the world and better position our products for future growth. We believe these efforts will enable us to drive sustainable long-term growth for Sight Sciences and create long-term value for our shareholders. That concludes our prepared remarks. We will now open the call up to questions from analysts.
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Sight Sciences. More…
| Total Revenues | Net Income | Net Margin |
| 71.33 | -86.24 | -120.9% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Sight Sciences. More…
| Operations | Investing | Financing |
| -71.19 | -0.81 | 252.53 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Sight Sciences. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 213.07 | 53 | 3.31 |
Key Ratios Snapshot
Some of the financial key ratios for Sight Sciences are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 45.1% | – | -114.6% |
| FCF Margin | ROE | ROA |
| -101.2% | -30.7% | -24.0% |
Share Price
The report showed that stock opened at $9.1 and closed at $9.4, a 1.5% increase from its previous closing price of 9.3. Overall, SIGHT SCIENCES‘ financial performance in the fourth quarter of FY2022 was positive, with strong year-over-year growth in all key areas. The company’s stock performance also reflected investor confidence in the company’s financial health. Live Quote…
Analysis – Sight Sciences Intrinsic Value
At GoodWhale, we strive to provide investors with accurate and up-to-date financial analysis of companies. For this reason, we recently conducted an in-depth study of SIGHT SCIENCES, a medical device company. Our analyses revealed that the intrinsic value of SIGHT SCIENCES’s share is currently around $20.2, calculated using our proprietary Valuation Line. However, it is currently traded at $9.4, representing a 53.4% discount to its intrinsic value. This could represent a great opportunity for an investor looking for undervalued stocks in this sector. More…
Peers
The global market for ophthalmology devices is growing rapidly, and Sight Sciences Inc is one of the leading companies in this industry. While there are many competitors in this space, Sight Sciences Inc has a strong position due to its innovative products and cutting-edge technology. The company is constantly striving to improve its products and stay ahead of the competition, which is evident in its strong financial performance and market share.
– Nova Eye Medical Ltd ($ASX:EYE)
Nova Eye Medical Ltd is a publicly traded company with a market capitalization of 38.65 million as of 2022. The company has a negative return on equity of 18.79%, meaning that it has lost shareholder value over the past year. Nova Eye Medical Ltd is a medical device company that manufactures and sells ophthalmic products, including contact lenses and intraocular lenses. The company has a strong presence in China and is expanding its operations into other markets, such as the United States.
– Acotec Scientific Holdings Ltd ($SEHK:06669)
Acotec Scientific Holdings Ltd is a holding company that operates in the life sciences sector. The company focuses on the research and development of new drugs and therapies. Acotec Scientific Holdings Ltd has a market cap of 2.6B as of 2022. The company’s Return on Equity for the same period is -3.65%.
– OncoSil Medical Ltd ($ASX:OSL)
OncoSil Medical Ltd is a medical device company that develops, manufactures, and commercializes products to treat cancer. The company has a market cap of 49.56M as of 2022 and a Return on Equity of -82.6%. OncoSil Medical’s products are designed to deliver radiation directly to cancerous tumors with minimal damage to surrounding healthy tissue. The company’s lead product, OncoSil, is a brachytherapy device that is approved for use in Australia, Europe, and Canada.
Summary
Investors should take note of the latest financial report released by SIGHT SCIENCES. The company reported a total revenue of -16.9 million USD, a 6.1% decrease compared to the same period the previous year.
However, net income was 20.5 million USD, a 39.9% increase year-over-year. This indicates that despite decreasing revenues, the company is still able to generate profit and is able to grow its business. Investors should further analyze the company’s performance and prospects before making a decision to invest in it.
